Navigation Links
Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan

g blood vessels, NFkB decoy which controls various inflammations, and HVJ envelope vector for non-viral drug delivery and discovery. Additional information on AnGes is available at www.anges-mg.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the potential approval of AnGes' HGF product candidate, as well as Vical's focus, collaborative partners, and product candidates. Risks and uncertainties include whether AnGes will file for marketing approval in Japan; whether the HGF product candidate will be approved in Japan; whether the market for the HGF product will be significant; whether any product candidates will be shown to be safe and effective in clinical trials; the timing, nature and cost of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any other product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

    Contacts:  Investors:                         Media:

               Alan R. Engbring                   Susan Neath

               Vical Incorporated                 Porter Novelli Life Sciences

               (858) 646-1127                     (619) 849-6007

               Website:  www.vical.com

CONTACT: Investors, Alan R. Engbring of Vical Incorporated,+1-858-646-1127; Media, Susan Neath of Porter Novelli Life Sciences,+1-619-849-6007

Web site
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
4. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:7/25/2014)... Dr. Michael Gabriel of a prominent Staten ... study, which shows how grief in pregnancy may cause obesity ... According to US News , "Unborn children ... others to grow up overweight or obese, even if that ... specific types of stress that caused obesity: "Children whose biological ...
(Date:7/24/2014)... , July 24, 2014  Restore Health, ... and compounded pharmaceuticals, announced that it is now ... unique to each individual based upon their particular ... by understanding the interaction between a patient,s genetics ... "We,re very excited to provide this new service ...
(Date:7/24/2014)... Calif., July 24, 2014  Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... First quarter overview: , Revenues of $47.5 million, ... Diluted EPS of $0.21, up 50% over last year,s ... market revenues of $7.2 million, up 20% over last ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... Bioness Inc., today announced the commercial release of its ... Drug Administration (FDA) earlier this year, the L300 Plus combines ... thigh cuff to activate even more of the nerves and ... The L300 Plus is intended for people ...
... LLC , a drug research and development company focused ... its compound CM-182 demonstrated positive results for reduction in ... screening was performed by the contract research organization, Cerca ... C57BL/6 mice exhibited a dose dependent reduction in hyperactivity ...
Cached Medicine Technology:Bioness Inc Announces Availability of L300 Plus System 2Curemark Reports Positive Results for Novel Compound CM-182 in Amphetamine Induced Hyperactivity 2
(Date:7/27/2014)... Manufacturers of natural ingredient beauty creams are ... a younger appearance. The Cherry News company has published ... and women explore the availabilities from U.S. retailers at ... in the posted guide on the Cherry News website ... drawback to some natural ingredient formulas is the high ...
(Date:7/27/2014)... CA (PRWEB) July 27, 2014 Ticket Down ... Tickets at The Forum in Inglewood, California on November 15th. ... and diehard fans can expect to hear songs from this amazing ... of Summer concert in Inglewood, California at The Forum will be ... starting at 10:00 a.m. today local time TicketDown.com. This popular ...
(Date:7/27/2014)... The constant expansion of companies across the globe has ... Additional factors that have increased this demand include the ... communication, learning and development, security and safety, and knowledge ... enterprise video market value has crossed $11.21 billion in ... 2018 with a compound annual growth rate (CAGR) of ...
(Date:7/27/2014)... The report, “Oil Filter & Fuel Filter Market ... Type (OE & Aftermarket), Filter Type (Oil & Fuel), ... Trends & Forecast to 2018”, defines and segments the ... and forecasting of the global volume and revenue. The ... a revenue of $6.1 billion in 2018, while fuel ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 The European Bromine ... with analysis and forecast of revenue. , Bromine market in ... France, Spain, and UK. Germany and France that forms a ... and its derivatives in Europe. , Browse through the ... idea of the in-depth analysis provided Browse through the TOC ...
Breaking Medicine News(10 mins):Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4
... risk factors for heart disease, including blood pressure and ... Association recommended Monday in new guidelines for the prevention ... the panel, observed that heart disease actually begins in ... make large changes in behavior early on. He said ...
... to a new research, a daily dose of a soybean ... "bad", or LDL, cholesterol levels in young men. Functional foods ... essential nutrients. //There has been a trend of adding value ... For example, Benecol Spread is a margarine that contains phytosterol ...
... Researchers say a daily teaspoon of lemon-flavored cod liver ... may help prevent middle ear infections in children. New ... infection,// required fewer antibiotics and had fewer ear infections ... oil, which has vitamins A and D and omega-3 ...
... Hopkins found a new study shows some cancer patients ... from treatment with the drug, interferon.,Past research has suggested ... B-cell non-Hodgkin's lymphoma's. //A patient with both of these ... patient responded causing researchers in Paris to study whether ...
... a new study which suggests hormone suppression therapy ... chances of living free of the disease.Michel Bolla, ... potential benefits of suppressing the male hormone androgen, ... testosterone, among 400 patients in advanced stages// of ...
... to take antibiotics before dental cleaning to reduce the ... drugs do not take them, sometimes because their doctors ... realize that the antibiotics are warranted, according to a ... that they say may increase compliance with the antibiotic ...
Cached Medicine News:Health News:Heart attack risk starts at 20 2Health News:Hormone Therapy applicable for Prostate Cancer 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: